Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer h358 cells

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 693-702

  Ling, Yi He ^d   Zou, Yiyu ^b   Perez Soler, Roman ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Department of Pathology   (United States)

^d NONE

Author keywords

Cell lung cancer cells; p53 gene transfection; Paclitaxel sensitivity; Senescence

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; DNA; LIPOSOME; PACLITAXEL; PROTEIN P53;

ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL LEVEL; CELL STRUCTURE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE INDUCTION; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL AGING; CELL CYCLE; CELL SURVIVAL; GENES, P53; HUMANS; KINETICS; LUNG NEOPLASMS; PACLITAXEL; PHENOTYPE; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034093592     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sarosy GI, and Reed E: Taxol dose intensification and its clinical implications. J Natl Med Assoc 85: 427-431, 1943.
2. Rowaisky EK: Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacol Ther 28: S18-S22, 1994.
3. Horwitz S B: Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136, 1992.
4. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
5. Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R: Accumulation of cyclin B1, activation of cyclin B1-dependent kinjase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 75: 925-932, 1998.
6. Lane DP: P53, the guardian of the genome. Nature (London) 358: 15-16, 1992.
7. Dulic V, Kaufman WK, Wilson SJ, Tlsty T, Lees E, Harper JW, Elledge SJ, Reed SI: P53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
8. Selivanova G, Wiman KG: P53, A cell cycle regulator activated by DNA damage. Adv Cancer Res 66: 143-180,1995.
9. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RJ, Raskind WH, Reid, BJ: A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356, 1995.
10. Wahl AF, Donalson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79, 1996.
11. Wu GS, and El-Deiry WS: P53 and chemosensitivity. Nature Med 2: 255-256, 1996.
12. Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford-Thomas D, Wyllie FS: Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SKI1/WAF1. Cancer Res 55: 2404-2409, 1995.
13. Morcer WE, Schields MT, Amin M, Sauve GJ, Appella E, Romana JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87: 6166-6170, 1990.
14. Zou Y, Zong G, Ling, YH, Hao MM, Lozno G, Hong WK, Perez-Soler R: Effective treatment of early endobronchial malignancy with the regional administration of liposome-p53 complexes. J Natl Cancer Inst 90: 1130-1137, 1998.
15. Sugrue MM, Shin DY, Lee SW, Aaronson ST: Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 94: 9648-9653, 1997.
16. King KL, Jackson PK, Kirschner MW: Mitosis ill transition. Cell 79: 563-571, 1994.
17. Lowe SW, Ruley HE, Jacks T, Housman DB: p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
18. Symond H, Krall L, Treminngton L, Saenz-Robles M, Lowes S, Jacks T, Van Dyke T: P53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711, 1994.
19. El-Deiry WS, Harpper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, BurrellL M, Hill DE, Wang, Y et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
20. Aas T, Borresen, A-L, Geilsen S, Smith-Sorensen B, Johsen H, Vargaug J E, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistant to doxorubicin in breast cancer patients. Nature Med 2: 811-814, 1996.
21. Smith JR, Pereira-Smith OM: Replicative senescence: implications for in vivo aging and tumor suppression. Science 273: 63-67, 1996.
22. Serrano M, Lin AW, Mecurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p161NK4a. Cell 88: 593-602, 1997.
23. Miyashida T, Krajewski S, Krajewski M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reer JC: Tumor suppressor p53 is a regulator of bel-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
24. 6-methylguanine-DNA methyltransferase gene. Cancer Res 56: 2029-2032, 1996.
25. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Motoh M, Schudiero DA, Monks A, Sausville E A, Weinstein J N, Frend S, Fornace A J, Kohn KW: Characterization of p53 tumor suppressor pathway in cell lines of the NCI anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
26. Hawkinns DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
27. Lanni JS, Jack T: Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18: 1055-1064, 1998.